Recent News and Updates in Kidney Cancer

In honor of Kidney Cancer Awareness Month, CURE® compiled some recent kidney cancer news and updates patients may have missed.

There have been multiple updates in the field of kidney cancer over the past several weeks. In honor of Kidney Cancer Awareness Month, CURE® looks back at some of the latest news and updates affecting patients with that cancer type.

  • A higher starting dose of Lenvima (lenvatinib), compared with a lower starting dose, prolonged the time that patients with renal cell carcinoma experienced negative effects on factors including social and physical functioning, financial difficulties and cogitative functioning over time. READ MORE.
  • Recent study results, according to one expert, show that Cabometyx (cabozantinib) should be considered the new standard for systemic therapy in patients with metastatic papillary renal cell carcinoma. READ MORE.
  • The Food and Drug Administration recently granted approval to Fotivda (tivozanib) in adults with relapsed or refractory advanced renal cell carcinoma who have received two or more prior systemic therapies. READ MORE.
  • The combination of Cabometyx (cabozantinib) plus Opdivo (nivolumab) “is certainly going to become one of the new standards of care” for the treatment of advanced renal cell carcinoma now that the regimen is approved, according to an expert from the Dana-Farber Cancer Institute. READ MORE.
  • Positive results from the phase 3 CLEAR clinical trial are just one more dataset that could offer “a sense of hope and promise” for patients with advanced renal cell carcinoma, says the study’s lead author, Dr. Robert J. Motzer. WATCH HERE.
  • Patients with metastatic renal cell carcinoma older than 75 years experienced more toxicity with mTOR inhibitors, tyrosine kinase inhibitors and checkpoint immunotherapy compared with those younger than 75 years, but researchers found that age did not impact outcomes like progression-free survival and overall survival. READ MORE.

For more news on cancer updates, research and education, don’t forget to subscribe to CURE®’s newsletters here.